Takeda unit urges Fed Circ to revive antibody patent

Baxalta, a subsidiary of Japan-headquartered pharmaceutical company Takeda, has asked the US Court of Appeals for the Federal Circuit to overturn a decision that invalidated its antibody patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Semaglutide patent battle heats up with new blow for Novo in India

6 February 2026 A Delhi High Court ruling signals more bad news for the Danish pharma giant in the same week that it lost nearly $50 billion in value.

Careers

Wilson Sonsini senior counsel moves to a rival firm

6 February 2026 The New York-based partner will advise biotech, pharma, and technology clients on patent prosecution, IP strategy and venture-backed transactions.

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

More features

Semaglutide patent battle heats up with new blow for Novo in India

Wilson Sonsini senior counsel moves to a rival firm

AstraZeneca partners with Chinese firm ahead of next obesity race

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Nine-partner litigation team leaves Winston & Strawn

Squire Patton Boggs brings in tech and data expert as Ireland practice lead

LSPN Awards USA returns for second year—with new categories

Drowning in EU regulations? Five tips for surviving the deluge of new rules

Takeda unit urges Fed Circ to revive antibody patent

More on this story

Editor's picks

Editor's picks

More features